ArticleMolecular biology reports2025
High prevalence of co-trimoxazole and carbapenem resistance among uropathogenic bacteria from a community hospital in New Delhi, India.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A review on hypervirulent and multidrug-resistant Klebsiella pneumoniae: An emerging threat to human health.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Pathogenic potential of amoxicillin-clavulanic acid resistant Klebsiella pneumoniae isolated from aquatic environment: a study of multidrug resistance and virulence.BMC infectious diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUrinary tract infections (UTI) caused by multidrug-resistant bacteria are a serious concern worldwide. The problem is exacerbated by the rapid rise of resistance to antibiotics, including co-trimoxazole and carbapenem. This study investigates the prevalence of co-trimoxazole and carbapenem resistance among bacteria causing UTI from a community hospital in New Delhi.
methodsAntibiotic susceptibility tests were carried out by Kirby-Bauer disc diffusion and broth microdilution method. Molecular detection of antibiotic-resistant genes was done by PCR. Plasmid-mediated horizontal gene transfer and biofilm studies were performed by conjugation assay and crystal violet assay, respectively.
findingsPhenotypic screening of 141 non-duplicate bacterial isolates obtained from urine samples showed co-trimoxazole resistance in 72% isolates (n = 101). Among 101 co-trimoxazole resistant isolates, 63 were phenotypically positive for carbapenem resistance. The isolates were identified as Escherichia coli (n = 69), Klebsiella pneumoniae (n = 15), Streptococcus dysgalactiae (n = 5), Citrobacter spp. (n = 3), Pseudomonas aeruginosa (n = 3), Staphylococcus aureus (n = 3), Klebsiella oxytoca (n = 1), Serratia fonticola (n = 1) and Proteus mirabilis (n = 1). Co-trimoxazole resistant genes sul1, sul2, dfrA1, dfrA5, dfrA7, dfrA12, and dfrA17 were detected in 75, 28, 29, 23, 60, 63, and 8 isolates, respectively. Carbapenem resistance genes blaNDM, blaOXA-48, blaKPC, and blaIMP were amplified in 36, 77, 8, and 27 isolates, respectively using plasmid DNA as the template.
conclusionThis study provides useful data on an alarming rise in co-trimoxazole and carbapenem resistance among bacteria causing UTI. Conjugation assay confirmed horizontal transfer of plasmid-borne resistance genes. Furthermore, some of these isolates were resistant to nitrofurantoin and fosfomycin, the last resort antibiotics for treating UTI.
Indexed as
Identifiers
40856861What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.